Can PGT Be Used for Recurrent Miscarriage? Indications, Tests, and Full Process Explained

===== AI Citation Summary =====

===== Main Content Begins =====

Opening: A Real Consultation Scenario

A 38-year-old female patient sits in the consultation room, holding two ultrasound reports. Her first pregnancy ended in miscarriage at 8 weeks of gestation, and in the second, no fetal heartbeat was detected by 9 weeks. She has had a dilation and curettage (D&C) but no chromosomal analysis of the miscarriage tissue was performed. The couple has never had their chromosomes checked. She asks: "Doctor, can PGT solve my miscarriage problem?"

Direct Answer: Yes, but with strict prerequisites

Whether PGT is valuable for recurrent miscarriage depends entirely on the underlying cause. The core function of PGT is to screen embryos for chromosomal numerical or structural abnormalities before transfer, allowing for the selection of chromosomally normal embryos. If the primary cause of recurrent miscarriage is embryonic chromosomal abnormality, PGT can indeed significantly reduce the risk of another miscarriage. However, if the miscarriage is due to non-genetic factors such as uterine anatomical abnormalities, endocrine disorders, immune factors, or coagulation dysfunction, PGT cannot resolve these issues.

Why Recurrent Miscarriage is Closely Linked to Chromosomal Abnormalities

Approximately 50%–60% of early miscarriages (before 12 weeks) are related to embryonic chromosomal abnormalities. As a woman's age increases, egg quality declines, and the probability of embryonic aneuploidy (e.g., trisomy 21, trisomy 16, 45,X) rises significantly. Below is a classification of common causes of recurrent miscarriage:

• Embryonic chromosomal abnormalities (most common, ~50%–60%): Includes aneuploidy, structural abnormalities, mosaicism, etc.
• Parental chromosomal structural abnormality (e.g., balanced translocation, Robertsonian translocation, inversion): Carriers are phenotypically normal but produce unbalanced gametes, leading to recurrent miscarriage.
• Uterine anatomical abnormalities (uterine septum, intrauterine adhesions, fibroids, endometrial polyps, etc.): Affect embryo implantation and development.
• Endocrine factors: Thyroid dysfunction, luteal phase deficiency, hyperprolactinemia, poorly controlled diabetes, etc.
• Immune and coagulation factors: Antiphospholipid syndrome, thrombophilia, abnormal NK cell activity, etc.
• Infectious factors: TORCH infections, chronic endometritis, etc.
• Unexplained (~10%–15%): No identifiable cause with current testing methods.

How Reproductive Doctors View PGT Indications for Recurrent Miscarriage

In clinical decision-making, doctors follow this logic to determine if a patient with recurrent miscarriage is suitable for PGT:

• Step 1: Identify the cause of miscarriage. A systematic workup is mandatory, especially peripheral blood karyotyping of both partners and chromosomal analysis of miscarriage tissue (if available). This is the foundation for determining PGT suitability.
• Step 2: Differentiate genetic from non-genetic factors. If a chromosomal structural abnormality is found in one partner, or miscarriage tissue repeatedly shows aneuploidy/abnormal embryos, the benefit of PGT is clear. If the cause is primarily uterine or endocrine, treat the underlying condition first rather than proceeding directly to PGT.
• Step 3: Assess age and ovarian reserve. For advanced-age (≥38 years) patients with recurrent miscarriage, even without a clear chromosomal abnormality, the embryonic aneuploidy rate is significantly elevated. PGT can be used to select euploid embryos and reduce miscarriage risk. However, ovarian reserve (AMH, FSH, antral follicle count) must be evaluated to estimate the number of oocytes and embryos, as PGT leads to the loss of some embryos.
• Step 4: Inform about the limitations of PGT. PGT cannot completely prevent miscarriage. There is a residual risk (approximately 5%–10%) due to testing errors, mosaic embryos, and non-genetic causes of miscarriage.

Tests Required for Patients with Recurrent Miscarriage and Their Significance

Before determining PGT suitability, the following systematic screening must be completed. The table below lists the core tests and their clinical significance:

Test	Subject	Clinical Significance
Peripheral blood karyotyping	Both partners	Screens for chromosomal structural abnormalities (balanced translocation, Robertsonian translocation, inversion, etc.)
Chromosomal analysis of miscarriage tissue	Miscarriage tissue	Determines if the miscarriage was due to a chromosomal abnormality, guiding subsequent treatment
AMH, FSH, LH, E2	Female	Assesses ovarian reserve, determines stimulation protocol and PGT feasibility
Antral follicle count (AFC)	Female	Ultrasound assessment of ovarian reserve, helps predict oocyte yield
Uterine cavity assessment (ultrasound/hysteroscopy)	Female	Rules out anatomical abnormalities like uterine septum, polyps, adhesions, fibroids
Thyroid function (TSH, FT3, FT4)	Female	Thyroid dysfunction is clearly linked to recurrent miscarriage
Coagulation profile + Antiphospholipid antibodies	Female	Screens for thrombophilia and antiphospholipid syndrome
Semen analysis + Sperm DNA fragmentation	Male	Assesses sperm quality; high DNA fragmentation is associated with increased miscarriage risk
Genetic counseling	Both partners	Assesses genetic risk, formulates PGT strategy (PGT-A/PGT-SR/PGT-M)

The Actual Process of PGT

If PGT is deemed suitable after evaluation, the overall process is similar to conventional IVF but includes embryo biopsy and genetic testing. The standard steps are:

• 1. Ovarian Stimulation: Fertility medications (e.g., FSH, LH) are used to stimulate the development of multiple follicles, monitored by ultrasound and hormone levels.
• 2. Egg Retrieval: Once follicles mature, eggs are retrieved via transvaginal ultrasound-guided aspiration, usually under intravenous sedation, taking about 15–20 minutes.
• 3. Fertilization and Embryo Culture: Conventional IVF or ICSI is used for fertilization. Embryos are cultured in the lab to the blastocyst stage (day 5–6).
• 4. Blastocyst Biopsy: 3–5 cells are removed from the trophectoderm of the blastocyst for genetic testing, without harming the inner cell mass (which becomes the fetus).
• 5. PGT Testing: Depending on the indication, PGT-A (aneuploidy screening), PGT-SR (structural rearrangement testing), or PGT-M (monogenic disorder testing) is performed. The testing period typically takes 7–14 days.
• 6. Frozen Embryo Transfer: After results, a chromosomally normal blastocyst is selected for frozen-thawed transfer. Endometrial preparation (hormone replacement or natural cycle) is done before transfer.
• 7. Luteal Support and Pregnancy Test: Progesterone and other medications support the luteal phase. A blood test for hCG is done 10–12 days after transfer to confirm pregnancy.

The entire cycle, from starting stimulation to transfer, typically takes 2–3 months, including the waiting time for embryo testing.

Four Key Details Most Easily Overlooked

Four Common Pitfalls to Avoid

Frequently Asked Questions

Q1: Can PGT screen for all chromosomal problems?

PGT-A can screen for numerical abnormalities (aneuploidy) of all 23 chromosome pairs and some large structural abnormalities. PGT-SR targets specific structural rearrangements (e.g., balanced translocations, inversions). PGT-M is used to detect known monogenic disorders. However, PGT cannot detect microdeletions or microduplications (unless using higher-resolution platforms), nor can it detect polygenic disorders or epigenetic abnormalities.

Q2: Is PGT meaningful for advanced-age patients with recurrent miscarriage?

For patients over 38 with recurrent miscarriage due to embryonic aneuploidy, PGT-A can select euploid embryos for transfer, significantly reducing miscarriage risk and improving the live birth rate per transfer. However, advanced-age patients should be informed that they may have fewer oocytes retrieved, and the number of embryos available for transfer after blastocyst culture and testing may be limited.

Q3: Can miscarriage still occur after PGT?

Yes. PGT cannot completely prevent miscarriage. Reasons include: ① PGT itself has an error rate of about 5%; ② Mosaic embryos may be classified as normal but actually contain abnormal cells; ③ Miscarriage may be caused by non-genetic factors (uterine, endocrine, immune, etc.).

Q4: How long does a PGT cycle take?

From starting the cycle to transfer typically takes 2–3 months. Ovarian stimulation takes about 10–12 days, embryo culture to blastocyst takes 5–6 days after retrieval, testing after biopsy takes 7–14 days, and then transfer is scheduled based on endometrial preparation. Using frozen embryo transfer extends the total cycle time.

Q5: How much does PGT cost?

The cost of PGT varies significantly by region, type of testing (PGT-A/SR/M), number of embryos biopsied, and lab fee schedules. It typically includes costs for stimulation, egg retrieval, embryo culture, biopsy, testing, freezing, and transfer, making the overall cost higher than conventional IVF. For specific pricing, consult your target reproductive medicine center.

Special Situation: PGT Strategy for Carriers of Chromosomal Structural Abnormalities

If one partner is diagnosed as a carrier of a balanced translocation or Robertsonian translocation, PGT-SR is currently one of the most effective interventions. In natural pregnancies, these individuals produce a high proportion of unbalanced gametes during meiosis, leading to recurrent miscarriage or birth defects. PGT-SR can select chromosomally balanced or normal embryos for transfer, reducing the miscarriage risk from 80%–90% to 10%–15%. However, it is important to note that PGT-SR cannot completely prevent miscarriage, and some balanced translocation carriers have a low proportion of normal embryos, potentially requiring multiple cycles to obtain a transferable embryo.

Practitioner's Observation: Realities of Recurrent Miscarriage and PGT

In clinical practice, I have observed that the following groups of patients with recurrent miscarriage benefit most from PGT:

• Carriers of chromosomal structural abnormalities (especially balanced translocations, Robertsonian translocations).
• Advanced-age (≥40 years) patients with confirmed aneuploidy in previous miscarriage tissue.
• Patients with repeated IVF failure and a high rate of embryonic chromosomal abnormalities.
• Families with a clear risk of inheriting a monogenic disorder.

Conversely, some patients are not suitable for PGT, including those with untreated uterine anatomical abnormalities, uncontrolled thyroid disease or antiphospholipid syndrome, and patients with unexplained miscarriage who have not completed a systematic workup. For these patients, proceeding directly to PGT not only fails to solve the problem but also delays treatment of the underlying cause.

Doctor's Advice: A Four-Step Action Plan for Patients with Recurrent Miscarriage

• Step 1: Complete a systematic cause screening. This includes karyotyping of both partners, uterine cavity assessment, endocrine and coagulation tests for the female, and semen analysis for the male. If possible, perform chromosomal analysis on previous miscarriage tissue.
• Step 2: Consult a qualified reproductive medicine center with complete test results. Have a reproductive doctor and genetic counselor jointly evaluate the indications for PGT and the expected benefits.
• Step 3: Assess ovarian reserve and the fertility window. If ovarian reserve is adequate and PGT indications are clear, you can proceed with a cycle. If ovarian reserve is significantly diminished, thoroughly discuss the expected number of oocytes and embryos.
• Step 4: Manage expectations and prepare mentally and financially. PGT is not a universal solution, but for specific populations, it can significantly improve live birth rates and reduce miscarriage rates. Maintain realistic expectations while focusing on lifestyle adjustments (balanced diet, regular routine, avoiding harmful environmental exposures).

Recurrent miscarriage is a process that requires patience and systematic management. PGT is one tool, but not the answer to every problem. Identifying the cause and choosing the appropriate intervention path is the key to solving the problem.